Company Showcase


Established in 2008, Rhizen is a private clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation. Their pipeline covers   PI3Kδγ inhibitor, SOCE inhibitor, DHODH inhibitor, and glutamic acid, etc. They have partnership with Novartis and TG Therapeutics with PI3Kδγ inhibitor products.

Rhizen 创立于2008年,总部位于瑞士,是一家私有的位于临床阶段的生物制药公司,公司专注于肿瘤和炎症免疫类小分子靶向药物开发,产品管线覆盖了多种PI3K通路抑制剂, SOCE抑制剂,DHODH抑制剂及谷酰胺酶抑制剂等,其中已有两款PI3K产品分别与Novartis和TG

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s